Related Experiment Video
Updated: Apr 8, 2026
05:19
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
1.1K
Comparative Detection Performance of PSMA and Non-PSMA PET Tracers in Recurrent and Primary Prostate Cancer: A
Yu-Erh Huang1, Cheng-Kai Huang2, Ya-Ting Huang3,4
1Department of Nuclear Medicine, Jen-Ai Hospital, Taichung.
Clinical Nuclear Medicine
|April 7, 2026
Summary
Prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) tracers show higher detection rates for prostate cancer recurrence than other agents. Among PSMA tracers, 18F-labeled agents are superior to 68Ga-PSMA-11 for both primary and recurrent disease.
Area of Science:
- Nuclear Medicine
- Oncology Imaging
- Radiopharmaceuticals
Background:
- Prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) imaging has advanced prostate cancer (PC) diagnostics.
- Existing comparative data on the performance of various PSMA and non-PSMA PET tracers are limited.
- Optimal tracer selection for PC imaging remains an area of active investigation.
Purpose of the Study:
- To conduct a systematic review and network meta-analysis (NMA) of detection rates (DRs) for PET tracers in primary and biochemically recurrent prostate cancer.
- To directly compare the performance of different PSMA-targeted and non-PSMA PET tracers.
- To identify the most effective PET tracers for prostate cancer detection.
Main Methods:
- Systematic literature search of PubMed, Embase, Cochrane Library, and ClinicalTrials.gov up to March 2025.
- Inclusion of studies comparing two PET tracers for prostate cancer, with detection rate as the primary outcome.
- Frequentist random-effects network meta-analysis (NMA) using 68Ga-PSMA-11 as the reference standard.
Main Results:
- PSMA-directed tracers demonstrated significantly higher detection rates compared to non-PSMA probes in biochemically recurrent PC.
- Among PSMA tracers, 64Cu-PSMA-617 showed the highest estimated DR, followed by 18F-DCFPyL, 18F-PSMA-1007, and 68Ga-PSMA-11.
- 18F-PSMA-1007 and 18F-DCFPyL exhibited superior DRs compared to 68Ga-PSMA-11 in both primary and recurrent PC settings.
Conclusions:
- PSMA-targeted PET tracers are more effective than non-PSMA alternatives for detecting biochemical recurrence in prostate cancer.
- 18F-labeled PSMA tracers consistently outperform 68Ga-PSMA-11 in detecting both primary and recurrent prostate cancer.
- 18F-labeled PSMA tracers represent the preferred imaging option when clinically available.
More Related Videos
Related Concept Videos
01:29Positron Emission Tomography
8.1K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
8.1K
01:25Imaging Studies II: Positron Emission Tomography and Scintigraphy
763
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
Fundamental Principles of PET
763